APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chronic Kidney Disease Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Chronic Kidney Disease Drugs Industry Growth and Trends Forecast to 2032

26 December 2025102 pages

Choose your research edition.

Industry ResearchChronic Kidney Disease Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Chronic Kidney Disease Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Chronic Kidney Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chronic Kidney Disease Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Chronic Kidney Disease Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Chronic Kidney Disease Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Chronic Kidney Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Chronic Kidney Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chronic Kidney Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Chronic Kidney Disease Drugs include AstraZeneca, F. Hoffmann-La Roche Ltd, Keryx Biopharmaceuticals, Inc, Kissei Pharmaceutical Co., Ltd, AbbVie, Amgen, GlaxoSmithKline, Pfizer and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Chronic Kidney Disease Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Chronic Kidney Disease Drugs market size, estimates, and forecasts are presented in terms of sales volume (W Tons) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Chronic Kidney Disease Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Chronic Kidney Disease Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Chronic Kidney Disease Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Chronic Kidney Disease Drugs Market by Company

AstraZeneca

F. Hoffmann-La Roche Ltd

Keryx Biopharmaceuticals, Inc

Kissei Pharmaceutical Co., Ltd

AbbVie

Amgen

GlaxoSmithKline

Pfizer

Sanofi

Teva Pharmaceutical Industries

Chronic Kidney Disease Drugs Segment by Type

Beta Blockers

Calcium Channel Blockers

Others

ACE Inhibitors

Chronic Kidney Disease Drugs Segment by Application

Hospitals

Specialty Clinics

Chronic Kidney Disease Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Kidney Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chronic Kidney Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Kidney Disease Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Chronic Kidney Disease Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Chronic Kidney Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Beta Blockers Table 2. Major Company of Calcium Channel Blockers Table 3. Major Company of Others Table 4. Major Company of ACE Inhibitors Table 5. Global Chronic Kidney Disease Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Chronic Kidney Disease Drugs Sales by Type (2021-2026) & (W Tons) Table 7. Global Chronic Kidney Disease Drugs Sales Market Share in Volume by Type (2021-2026) Table 8. Global Chronic Kidney Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 9. Global Chronic Kidney Disease Drugs Sales Market Share in Value by Type (2021-2026) Table 10. Global Chronic Kidney Disease Drugs Price by Type (2021-2026) & (US$/Ton) Table 11. Global Chronic Kidney Disease Drugs Sales by Type (2027-2032) & (W Tons) Table 12. Global Chronic Kidney Disease Drugs Sales Market Share in Volume by Type (2027-2032) Table 13. Global Chronic Kidney Disease Drugs Sales by Type (2027-2032) & (US$ Million) Table 14. Global Chronic Kidney Disease Drugs Sales Market Share in Value by Type (2027-2032) Table 15. Global Chronic Kidney Disease Drugs Price by Type (2027-2032) & (US$/Ton) Table 16. North America Chronic Kidney Disease Drugs Sales by Type (2021-2026) & (W Tons) Table 17. North America Chronic Kidney Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Chronic Kidney Disease Drugs Sales by Type (2021-2026) & (W Tons) Table 19. Europe Chronic Kidney Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Chronic Kidney Disease Drugs Sales by Type (2021-2026) & (W Tons) Table 21. Asia-Pacific Chronic Kidney Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Chronic Kidney Disease Drugs Sales by Type (2021-2026) & (W Tons) Table 23. Latin America Chronic Kidney Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Chronic Kidney Disease Drugs Sales by Type (2021-2026) & (W Tons) Table 25. Middle East and Africa Chronic Kidney Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 26. Chronic Kidney Disease Drugs Industry Trends Table 27. Chronic Kidney Disease Drugs Industry Drivers Table 28. Chronic Kidney Disease Drugs Industry Opportunities and Challenges Table 29. Chronic Kidney Disease Drugs Industry Restraints Table 30. Global Chronic Kidney Disease Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Chronic Kidney Disease Drugs Revenue Market Share by Company (2021-2026) Table 32. Global Chronic Kidney Disease Drugs Sales by Company (2021-2026) & (W Tons) Table 33. Global Chronic Kidney Disease Drugs Sales Share by Company (2021-2026) Table 34. Global Chronic Kidney Disease Drugs Market Price by Company (2021-2026) & (US$/Ton) Table 35. Global Chronic Kidney Disease Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Chronic Kidney Disease Drugs Major Company Production Sites and Headquarters Table 37. Global Chronic Kidney Disease Drugs Company, Product Type & Application Table 38. Global Chronic Kidney Disease Drugs Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Chronic Kidney Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Chronic Kidney Disease Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Chronic Kidney Disease Drugs Sales by Region (2021-2026) & (W Tons) Table 43. Global Chronic Kidney Disease Drugs Sales Market Share in Volume by Region (2021-2026) Table 44. Global Chronic Kidney Disease Drugs Sales by Region (2021-2026) & (US$ Million) Table 45. Global Chronic Kidney Disease Drugs Sales Market Share in Value by Region (2021-2026) Table 46. Global Chronic Kidney Disease Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 47. Global Chronic Kidney Disease Drugs Sales by Region (2027-2032) & (W Tons) Table 48. Global Chronic Kidney Disease Drugs Sales Market Share in Volume by Region (2027-2032) Table 49. Global Chronic Kidney Disease Drugs Sales by Region (2027-2032) & (US$ Million) Table 50. Global Chronic Kidney Disease Drugs Sales Market Share in Value by Region (2027-2032) Table 51. Global Chronic Kidney Disease Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2027-2032) Table 52. Global Chronic Kidney Disease Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Chronic Kidney Disease Drugs Sales by Application (2021-2026) & (W Tons) Table 54. Global Chronic Kidney Disease Drugs Sales Market Share in Volume by Application (2021-2026) Table 55. Global Chronic Kidney Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 56. Global Chronic Kidney Disease Drugs Sales Market Share in Value by Application (2021-2026) Table 57. Global Chronic Kidney Disease Drugs Price by Application (2021-2026) & (US$/Ton) Table 58. Global Chronic Kidney Disease Drugs Sales by Application (2027-2032) & (W Tons) Table 59. Global Chronic Kidney Disease Drugs Sales Market Share in Volume by Application (2027-2032) Table 60. Global Chronic Kidney Disease Drugs Sales by Application (2027-2032) & (US$ Million) Table 61. Global Chronic Kidney Disease Drugs Sales Market Share in Value by Application (2027-2032) Table 62. Global Chronic Kidney Disease Drugs Price by Application (2027-2032) & (US$/Ton) Table 63. North America Chronic Kidney Disease Drugs Sales by Application (2021-2026) & (W Tons) Table 64. North America Chronic Kidney Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Chronic Kidney Disease Drugs Sales by Application (2021-2026) & (W Tons) Table 66. Europe Chronic Kidney Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Chronic Kidney Disease Drugs Sales by Application (2021-2026) & (W Tons) Table 68. Asia-Pacific Chronic Kidney Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Chronic Kidney Disease Drugs Sales by Application (2021-2026) & (W Tons) Table 70. Latin America Chronic Kidney Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Chronic Kidney Disease Drugs Sales by Application (2021-2026) & (W Tons) Table 72. Middle East and Africa Chronic Kidney Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 73. AstraZeneca Company Information Table 74. AstraZeneca Business Overview Table 75. AstraZeneca Chronic Kidney Disease Drugs Sales (W Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 76. AstraZeneca Chronic Kidney Disease Drugs Product Portfolio Table 77. AstraZeneca Recent Development Table 78. F. Hoffmann-La Roche Ltd Company Information Table 79. F. Hoffmann-La Roche Ltd Business Overview Table 80. F. Hoffmann-La Roche Ltd Chronic Kidney Disease Drugs Sales (W Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 81. F. Hoffmann-La Roche Ltd Chronic Kidney Disease Drugs Product Portfolio Table 82. F. Hoffmann-La Roche Ltd Recent Development Table 83. Keryx Biopharmaceuticals, Inc Company Information Table 84. Keryx Biopharmaceuticals, Inc Business Overview Table 85. Keryx Biopharmaceuticals, Inc Chronic Kidney Disease Drugs Sales (W Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 86. Keryx Biopharmaceuticals, Inc Chronic Kidney Disease Drugs Product Portfolio Table 87. Keryx Biopharmaceuticals, Inc Recent Development Table 88. Kissei Pharmaceutical Co., Ltd Company Information Table 89. Kissei Pharmaceutical Co., Ltd Business Overview Table 90. Kissei Pharmaceutical Co., Ltd Chronic Kidney Disease Drugs Sales (W Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 91. Kissei Pharmaceutical Co., Ltd Chronic Kidney Disease Drugs Product Portfolio Table 92. Kissei Pharmaceutical Co., Ltd Recent Development Table 93. AbbVie Company Information Table 94. AbbVie Business Overview Table 95. AbbVie Chronic Kidney Disease Drugs Sales (W Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 96. AbbVie Chronic Kidney Disease Drugs Product Portfolio Table 97. AbbVie Recent Development Table 98. Amgen Company Information Table 99. Amgen Business Overview Table 100. Amgen Chronic Kidney Disease Drugs Sales (W Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 101. Amgen Chronic Kidney Disease Drugs Product Portfolio Table 102. Amgen Recent Development Table 103. GlaxoSmithKline Company Information Table 104. GlaxoSmithKline Business Overview Table 105. GlaxoSmithKline Chronic Kidney Disease Drugs Sales (W Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 106. GlaxoSmithKline Chronic Kidney Disease Drugs Product Portfolio Table 107. GlaxoSmithKline Recent Development Table 108. Pfizer Company Information Table 109. Pfizer Business Overview Table 110. Pfizer Chronic Kidney Disease Drugs Sales (W Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 111. Pfizer Chronic Kidney Disease Drugs Product Portfolio Table 112. Pfizer Recent Development Table 113. Sanofi Company Information Table 114. Sanofi Business Overview Table 115. Sanofi Chronic Kidney Disease Drugs Sales (W Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 116. Sanofi Chronic Kidney Disease Drugs Product Portfolio Table 117. Sanofi Recent Development Table 118. Teva Pharmaceutical Industries Company Information Table 119. Teva Pharmaceutical Industries Business Overview Table 120. Teva Pharmaceutical Industries Chronic Kidney Disease Drugs Sales (W Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 121. Teva Pharmaceutical Industries Chronic Kidney Disease Drugs Product Portfolio Table 122. Teva Pharmaceutical Industries Recent Development Table 123. North America Chronic Kidney Disease Drugs Market Size Growth Rate (CAGR) by Country (W Tons): 2021 VS 2025 VS 2032 Table 124. North America Chronic Kidney Disease Drugs Sales by Country (2021-2026) & (W Tons) Table 125. North America Chronic Kidney Disease Drugs Sales Market Share by Country (2021-2026) Table 126. North America Chronic Kidney Disease Drugs Sales Forecast by Country (2027-2032) & (W Tons) Table 127. North America Chronic Kidney Disease Drugs Sales Market Share Forecast by Country (2027-2032) Table 128. North America Chronic Kidney Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. North America Chronic Kidney Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 130. North America Chronic Kidney Disease Drugs Market Share by Country (2021-2026) Table 131. North America Chronic Kidney Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. North America Chronic Kidney Disease Drugs Market Share Forecast by Country (2027-2032) Table 133. Europe Chronic Kidney Disease Drugs Market Size Growth Rate (CAGR) by Country (W Tons): 2021 VS 2025 VS 2032 Table 134. Europe Chronic Kidney Disease Drugs Sales by Country (2021-2026) & (W Tons) Table 135. Europe Chronic Kidney Disease Drugs Sales Market Share by Country (2021-2026) Table 136. Europe Chronic Kidney Disease Drugs Sales Forecast by Country (2027-2032) & (W Tons) Table 137. Europe Chronic Kidney Disease Drugs Sales Market Share Forecast by Country (2027-2032) Table 138. Europe Chronic Kidney Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Europe Chronic Kidney Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 140. Europe Chronic Kidney Disease Drugs Market Share by Country (2021-2026) Table 141. Europe Chronic Kidney Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Europe Chronic Kidney Disease Drugs Market Share Forecast by Country (2027-2032) Table 143. Asia-Pacific Chronic Kidney Disease Drugs Market Size Growth Rate (CAGR) by Country (W Tons): 2021 VS 2025 VS 2032 Table 144. Asia-Pacific Chronic Kidney Disease Drugs Sales by Country (2021-2026) & (W Tons) Table 145. Asia-Pacific Chronic Kidney Disease Drugs Sales Market Share by Country (2021-2026) Table 146. Asia-Pacific Chronic Kidney Disease Drugs Sales Forecast by Country (2027-2032) & (W Tons) Table 147. Asia-Pacific Chronic Kidney Disease Drugs Sales Market Share Forecast by Country (2027-2032) Table 148. Asia-Pacific Chronic Kidney Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Asia-Pacific Chronic Kidney Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 150. Asia-Pacific Chronic Kidney Disease Drugs Market Share by Country (2021-2026) Table 151. Asia-Pacific Chronic Kidney Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Asia-Pacific Chronic Kidney Disease Drugs Market Share Forecast by Country (2027-2032) Table 153. Latin America Chronic Kidney Disease Drugs Market Size Growth Rate (CAGR) by Country (W Tons): 2021 VS 2025 VS 2032 Table 154. Latin America Chronic Kidney Disease Drugs Sales by Country (2021-2026) & (W Tons) Table 155. Latin America Chronic Kidney Disease Drugs Sales Market Share by Country (2021-2026) Table 156. Latin America Chronic Kidney Disease Drugs Sales Forecast by Country (2027-2032) & (W Tons) Table 157. Latin America Chronic Kidney Disease Drugs Sales Market Share Forecast by Country (2027-2032) Table 158. Latin America Chronic Kidney Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Latin America Chronic Kidney Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 160. Latin America Chronic Kidney Disease Drugs Market Share by Country (2021-2026) Table 161. Latin America Chronic Kidney Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Latin America Chronic Kidney Disease Drugs Market Share Forecast by Country (2027-2032) Table 163. Middle East and Africa Chronic Kidney Disease Drugs Market Size Growth Rate (CAGR) by Country (W Tons): 2021 VS 2025 VS 2032 Table 164. Middle East and Africa Chronic Kidney Disease Drugs Sales by Country (2021-2026) & (W Tons) Table 165. Middle East and Africa Chronic Kidney Disease Drugs Sales Market Share by Country (2021-2026) Table 166. Middle East and Africa Chronic Kidney Disease Drugs Sales Forecast by Country (2027-2032) & (W Tons) Table 167. Middle East and Africa Chronic Kidney Disease Drugs Sales Market Share Forecast by Country (2027-2032) Table 168. Middle East and Africa Chronic Kidney Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Middle East and Africa Chronic Kidney Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 170. Middle East and Africa Chronic Kidney Disease Drugs Market Share by Country (2021-2026) Table 171. Middle East and Africa Chronic Kidney Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Middle East and Africa Chronic Kidney Disease Drugs Market Share Forecast by Country (2027-2032) Table 173. Key Raw Materials Table 174. Raw Materials Key Suppliers Table 175. Chronic Kidney Disease Drugs Distributors List Table 176. Chronic Kidney Disease Drugs Customers List Table 177. Research Programs/Design for This Report Table 178. Authors List of This Report Table 179. Secondary Sources Table 180. Primary Sources List of Figures Figure 1. Chronic Kidney Disease Drugs Image Figure 2. Global Chronic Kidney Disease Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chronic Kidney Disease Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Chronic Kidney Disease Drugs Sales (2021-2032) & (W Tons) Figure 5. Beta Blockers Image Figure 6. Global Beta Blockers Sales YoY Growth (2021-2032) & (W Tons) Figure 7. Calcium Channel Blockers Image Figure 8. Global Calcium Channel Blockers Sales YoY Growth (2021-2032) & (W Tons) Figure 9. Others Image Figure 10. Global Others Sales YoY Growth (2021-2032) & (W Tons) Figure 11. ACE Inhibitors Image Figure 12. Global ACE Inhibitors Sales YoY Growth (2021-2032) & (W Tons) Figure 13. Global Chronic Kidney Disease Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Chronic Kidney Disease Drugs Market Share by Type 2025 VS 2032 Figure 15. North America Chronic Kidney Disease Drugs Sales Market Share in Volume by Type in 2025 Figure 16. North America Chronic Kidney Disease Drugs Sales Market Share in Value by Type in 2025 Figure 17. Europe Chronic Kidney Disease Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Europe Chronic Kidney Disease Drugs Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Chronic Kidney Disease Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Chronic Kidney Disease Drugs Sales Market Share in Value by Type in 2025 Figure 21. Latin America Chronic Kidney Disease Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Chronic Kidney Disease Drugs Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Chronic Kidney Disease Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Chronic Kidney Disease Drugs Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Chronic Kidney Disease Drugs Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospitals Image Figure 28. Global Hospitals Sales YoY Growth (2021-2032) & (W Tons) Figure 29. Specialty Clinics Image Figure 30. Global Specialty Clinics Sales YoY Growth (2021-2032) & (W Tons) Figure 31. Global Chronic Kidney Disease Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Chronic Kidney Disease Drugs Market Share by Application 2025 VS 2032 Figure 33. North America Chronic Kidney Disease Drugs Sales Market Share in Volume by Application in 2025 Figure 34. North America Chronic Kidney Disease Drugs Sales Market Share in Value by Application in 2025 Figure 35. Europe Chronic Kidney Disease Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Europe Chronic Kidney Disease Drugs Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Chronic Kidney Disease Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Chronic Kidney Disease Drugs Sales Market Share in Value by Application in 2025 Figure 39. Latin America Chronic Kidney Disease Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Chronic Kidney Disease Drugs Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Chronic Kidney Disease Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Chronic Kidney Disease Drugs Sales Market Share in Value by Application in 2025 Figure 43. North America Chronic Kidney Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Tons) Figure 44. North America Chronic Kidney Disease Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Chronic Kidney Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Chronic Kidney Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Chronic Kidney Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Tons) Figure 48. Europe Chronic Kidney Disease Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Chronic Kidney Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Chronic Kidney Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Chronic Kidney Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Tons) Figure 52. Asia-Pacific Chronic Kidney Disease Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Chronic Kidney Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Chronic Kidney Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Chronic Kidney Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Tons) Figure 56. Latin America Chronic Kidney Disease Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Chronic Kidney Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Chronic Kidney Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Chronic Kidney Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Tons) Figure 60. Middle East and Africa Chronic Kidney Disease Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Chronic Kidney Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Chronic Kidney Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Chronic Kidney Disease Drugs Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Chronic Kidney Disease Drugs Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Beta Blockers
  • Calcium Channel Blockers
  • Others
  • ACE Inhibitors
Applications
  • Hospitals
  • Specialty Clinics
Companies covered
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Keryx Biopharmaceuticals, Inc
  • Kissei Pharmaceutical Co., Ltd
  • AbbVie
  • Amgen
  • GlaxoSmithKline
  • Pfizer
  • Sanofi
  • Teva Pharmaceutical Industries

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Chronic Kidney Disease Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Chronic Kidney Disease Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Chronic Kidney Disease Drugs Market by Type
  6. 1.3.1 Beta Blockers
  7. 1.3.2 Calcium Channel Blockers
  8. 1.3.3 Others
  9. 1.3.4 ACE Inhibitors
  10. 1.4 Global Chronic Kidney Disease Drugs Market Size by Type
  11. 1.4.1 Global Chronic Kidney Disease Drugs Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Chronic Kidney Disease Drugs Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Chronic Kidney Disease Drugs Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Chronic Kidney Disease Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Chronic Kidney Disease Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Chronic Kidney Disease Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Chronic Kidney Disease Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Chronic Kidney Disease Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Chronic Kidney Disease Drugs Industry Trends
  2. 2.2 Chronic Kidney Disease Drugs Industry Drivers
  3. 2.3 Chronic Kidney Disease Drugs Industry Opportunities and Challenges
  4. 2.4 Chronic Kidney Disease Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Chronic Kidney Disease Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Chronic Kidney Disease Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Chronic Kidney Disease Drugs Price (2021-2026)
  4. 3.4 Global Chronic Kidney Disease Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Chronic Kidney Disease Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Chronic Kidney Disease Drugs Company, Product Type & Application
  7. 3.7 Global Chronic Kidney Disease Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Chronic Kidney Disease Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Chronic Kidney Disease Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Chronic Kidney Disease Drugs Tier 1, Tier 2, and Tier 3
4 Chronic Kidney Disease Drugs Regional Status and Outlook
  1. 4.1 Global Chronic Kidney Disease Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Chronic Kidney Disease Drugs Historic Market Size by Region
  3. 4.2.1 Global Chronic Kidney Disease Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Chronic Kidney Disease Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Chronic Kidney Disease Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Chronic Kidney Disease Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Chronic Kidney Disease Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Chronic Kidney Disease Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Chronic Kidney Disease Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Chronic Kidney Disease Drugs by Application
  1. 5.1 Chronic Kidney Disease Drugs Market by Application
  2. 5.1.1 Hospitals
  3. 5.1.2 Specialty Clinics
  4. 5.2 Global Chronic Kidney Disease Drugs Market Size by Application
  5. 5.2.1 Global Chronic Kidney Disease Drugs Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Chronic Kidney Disease Drugs Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Chronic Kidney Disease Drugs Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Chronic Kidney Disease Drugs Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Chronic Kidney Disease Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Chronic Kidney Disease Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Chronic Kidney Disease Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Chronic Kidney Disease Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 AstraZeneca
  2. 6.1.1 AstraZeneca Company Information
  3. 6.1.2 AstraZeneca Business Overview
  4. 6.1.3 AstraZeneca Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 AstraZeneca Chronic Kidney Disease Drugs Product Portfolio
  6. 6.1.5 AstraZeneca Recent Developments
  7. 6.2 F. Hoffmann-La Roche Ltd
  8. 6.2.1 F. Hoffmann-La Roche Ltd Company Information
  9. 6.2.2 F. Hoffmann-La Roche Ltd Business Overview
  10. 6.2.3 F. Hoffmann-La Roche Ltd Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 F. Hoffmann-La Roche Ltd Chronic Kidney Disease Drugs Product Portfolio
  12. 6.2.5 F. Hoffmann-La Roche Ltd Recent Developments
  13. 6.3 Keryx Biopharmaceuticals, Inc
  14. 6.3.1 Keryx Biopharmaceuticals, Inc Company Information
  15. 6.3.2 Keryx Biopharmaceuticals, Inc Business Overview
  16. 6.3.3 Keryx Biopharmaceuticals, Inc Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Keryx Biopharmaceuticals, Inc Chronic Kidney Disease Drugs Product Portfolio
  18. 6.3.5 Keryx Biopharmaceuticals, Inc Recent Developments
  19. 6.4 Kissei Pharmaceutical Co., Ltd
  20. 6.4.1 Kissei Pharmaceutical Co., Ltd Company Information
  21. 6.4.2 Kissei Pharmaceutical Co., Ltd Business Overview
  22. 6.4.3 Kissei Pharmaceutical Co., Ltd Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Kissei Pharmaceutical Co., Ltd Chronic Kidney Disease Drugs Product Portfolio
  24. 6.4.5 Kissei Pharmaceutical Co., Ltd Recent Developments
  25. 6.5 AbbVie
  26. 6.5.1 AbbVie Company Information
  27. 6.5.2 AbbVie Business Overview
  28. 6.5.3 AbbVie Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 AbbVie Chronic Kidney Disease Drugs Product Portfolio
  30. 6.5.5 AbbVie Recent Developments
  31. 6.6 Amgen
  32. 6.6.1 Amgen Company Information
  33. 6.6.2 Amgen Business Overview
  34. 6.6.3 Amgen Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Amgen Chronic Kidney Disease Drugs Product Portfolio
  36. 6.6.5 Amgen Recent Developments
  37. 6.7 GlaxoSmithKline
  38. 6.7.1 GlaxoSmithKline Company Information
  39. 6.7.2 GlaxoSmithKline Business Overview
  40. 6.7.3 GlaxoSmithKline Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 GlaxoSmithKline Chronic Kidney Disease Drugs Product Portfolio
  42. 6.7.5 GlaxoSmithKline Recent Developments
  43. 6.8 Pfizer
  44. 6.8.1 Pfizer Company Information
  45. 6.8.2 Pfizer Business Overview
  46. 6.8.3 Pfizer Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Pfizer Chronic Kidney Disease Drugs Product Portfolio
  48. 6.8.5 Pfizer Recent Developments
  49. 6.9 Sanofi
  50. 6.9.1 Sanofi Company Information
  51. 6.9.2 Sanofi Business Overview
  52. 6.9.3 Sanofi Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Sanofi Chronic Kidney Disease Drugs Product Portfolio
  54. 6.9.5 Sanofi Recent Developments
  55. 6.10 Teva Pharmaceutical Industries
  56. 6.10.1 Teva Pharmaceutical Industries Company Information
  57. 6.10.2 Teva Pharmaceutical Industries Business Overview
  58. 6.10.3 Teva Pharmaceutical Industries Chronic Kidney Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Teva Pharmaceutical Industries Chronic Kidney Disease Drugs Product Portfolio
  60. 6.10.5 Teva Pharmaceutical Industries Recent Developments
7 North America by Country
  1. 7.1 North America Chronic Kidney Disease Drugs Sales by Country
  2. 7.1.1 North America Chronic Kidney Disease Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Chronic Kidney Disease Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Chronic Kidney Disease Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Chronic Kidney Disease Drugs Market Size by Country
  6. 7.2.1 North America Chronic Kidney Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Chronic Kidney Disease Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Chronic Kidney Disease Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Chronic Kidney Disease Drugs Sales by Country
  2. 8.1.1 Europe Chronic Kidney Disease Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Chronic Kidney Disease Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Chronic Kidney Disease Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Chronic Kidney Disease Drugs Market Size by Country
  6. 8.2.1 Europe Chronic Kidney Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Chronic Kidney Disease Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Chronic Kidney Disease Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Chronic Kidney Disease Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Chronic Kidney Disease Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Chronic Kidney Disease Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Chronic Kidney Disease Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Chronic Kidney Disease Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Chronic Kidney Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Chronic Kidney Disease Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Chronic Kidney Disease Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Chronic Kidney Disease Drugs Sales by Country
  2. 10.1.1 South America Chronic Kidney Disease Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Chronic Kidney Disease Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Chronic Kidney Disease Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Chronic Kidney Disease Drugs Market Size by Country
  6. 10.2.1 South America Chronic Kidney Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Chronic Kidney Disease Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Chronic Kidney Disease Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Chronic Kidney Disease Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Chronic Kidney Disease Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Chronic Kidney Disease Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Chronic Kidney Disease Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Chronic Kidney Disease Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Chronic Kidney Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Chronic Kidney Disease Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Chronic Kidney Disease Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Chronic Kidney Disease Drugs Value Chain Analysis
  2. 12.1.1 Chronic Kidney Disease Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Chronic Kidney Disease Drugs Production Mode & Process
  7. 12.2 Chronic Kidney Disease Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Chronic Kidney Disease Drugs Distributors
  10. 12.2.3 Chronic Kidney Disease Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst